NasdaqGS:PHATPharmaceuticals
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital
In late February 2026, Phathom Pharmaceuticals reported fourth-quarter and full-year 2025 results showing a much smaller net loss of US$21.15 million for the quarter and US$221.25 million for the year, alongside guidance for 2026 that includes expected operating profitability (excluding stock-based compensation) beginning in the third quarter.
The company also strengthened its financial position through a US$130 million equity raise, reworked term loans, and ongoing uptake of its VOQUEZNA...